(NASDAQ: CABA) Cabaletta Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.54%.
Cabaletta Bio's earnings in 2026 is -$181,318,000.On average, 11 Wall Street analysts forecast CABA's earnings for 2026 to be -$233,870,987, with the lowest CABA earnings forecast at -$257,369,986, and the highest CABA earnings forecast at -$204,726,125. On average, 10 Wall Street analysts forecast CABA's earnings for 2027 to be -$207,506,670, with the lowest CABA earnings forecast at -$225,970,169, and the highest CABA earnings forecast at -$181,583,172.
In 2028, CABA is forecast to generate -$200,114,489 in earnings, with the lowest earnings forecast at -$428,678,703 and the highest earnings forecast at -$88,485,768.